VistaGen Therapeutics (VTGN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VTGN VistaGen Therapeutics

Watchlist

3.1100
+0.0300+0.97%

Close Nov 1 16:00 ET

3.1100
0.00000.00%

Post 20:01 ET

84.14MMarket Cap-3344P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: VTGN to Report Financial Results Post-market on November 07
Moomoo NewsNov 1 10:45 ET
Press Release: Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
Dow JonesNov 1 08:31 ET
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
BusinesswireOct 9 08:30 ET
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
Yahoo FinanceSep 6 12:00 ET
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth
Yahoo FinanceSep 5 10:14 ET
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Moomoo NewsAug 15 08:31 ET · Ratings

Comments

Uncle Roger第一桶金

Oct 24 17:10

$VistaGen Therapeutics (VTGN.US)$
500k shares buy usd3!!

Uncle Roger第一桶金

Oct 1 08:34

$VistaGen Therapeutics (VTGN.US)$

Jaguar8

Sep 23 07:32

NEWS

$VistaGen Therapeutics (VTGN.US)$
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN) has initiated the PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray for the acute treatment of social anxiety disorder (SAD). This marks a significant milestone in the company's registration-directed PALISADE Phase 3 program. Fasedienol is designed for non-systemic, rapid activation of no...